Primary Sclerosing Cholangitis: Clinical Trials

34 trials for Primary Sclerosing Cholangitis, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

12 completed, 7 terminated, 5 recruiting, 4 withdrawn. 34 Phase 2, 4 Phase 3, 3 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 234Completed 12, Terminated 7, Recruiting 5, Withdrawn 4, Active not recruiting 3, Unknown 2, Not yet recruiting 1
Phase 34Terminated 2, Completed 1, Withdrawn 1
Phase 13Completed 1, Terminated 1, Unknown 1

Follow Primary Sclerosing Cholangitis: new trials by email Literature Review of Primary Sclerosing Cholangitis trials Research Report on Primary Sclerosing Cholangitis

Trials (filtered) newest first · largest first

All 34 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Nemolizumab for the Treatment of Moderate to Severe Chronic Hepatic Pruritus
Nemolizumab-ilto - Chronic Hepatic Pruritus, Cholestatic Liver Disease
Phase 2Not yet recruitingMayo Clinic152026-11-012026-09-28
A Study Evaluating the Safety, Tolerability, and Efficacy of Aramchol Meglumine in Primary Sclerosing Cholangitis
Aramchol meglumine - Primary Sclerosing Cholangitis
Phase 2WithdrawnGalmed Pharmaceuticals Ltd2025-06-012025-06-12
Pharmacologic Approaches to Preventing Primary Sclerosing Cholangitis Recurrence After Liver Transplantation
Fenofibrate (drug), Blood draw for the laboratory assessment, MRI using a hepatobiliary phase contrast agent (Gd-EOB-DPTA) - Primary Sclerosing Cholangitis, Liver Transplant, Complications
Phase 2RecruitingMayo Clinic802025-04-152026-07-17
A Multi-center Evaluation of Aldafermin in a Randomized, Double-blind, Placebo-controlled Study in Subjects With Primary Sclerosing Cholangitis.
aldafermin, Placebo - Primary Sclerosing Cholangitis
Phase 2 / Phase 3WithdrawnNGM Biopharmaceuticals, Inc2024-10-212025-05-07
The Effects of Bromelain Supplement in Patients With Ulcerative Colitis
Bromlein, Placebo - Ulcerative Colitis, Primary Sclerosing Cholangitis
Phase 2 / Phase 3CompletedNational Nutrition and Food Technology Institute522024-04-202026-10-27
FAecal Microbiota Transplantation in primaRy sclerosinG chOlangitis
Faecal Microbiota Transplant, FMT Placebo - Primary Sclerosing Cholangitis, Inflammatory Bowel Diseases
Phase 2RecruitingUniversity of Birmingham582024-03-272026-09-24
Detoxification of the Liver In PSC (Dolphin)
BRS201, Placebo - Primary Sclerosing Cholangitis
Phase 2RecruitingBrigham and Women's Hospital282023-12-122026-07-21
CS0159 in Chinese Patients With PSC (Primary Sclerosing Cholangitis)
CS0159 - Primary Sclerosing Cholangitis
Phase 2Active not recruitingCascade Pharmaceuticals, Inc502023-08-072026-03-13
Vancomycin in Primary Sclerosing Cholangitis in Italy
Oral Vancomycin, Placebo - Primary Sclerosing Cholangitis, Liver and Intrahepatic Bile Duct Disorder
Phase 2RecruitingUniversity of Milano Bicocca842023-06-152025-07-25
Oral Hymecromone to Treat Adolescents and Adults With Primary Sclerosing Cholangitis.
Hymecromone - Primary Sclerosing Cholangitis
Phase 2RecruitingAparna Goel242023-05-102025-06-13
Safety and Tolerability of A3907 in Primary Sclerosing Cholangitis
Ritivixibat - Primary Sclerosing Cholangitis
Phase 2TerminatedAlbireo, an Ipsen Company182023-01-092026-05-04
A Study to Assess Safety and Effectiveness of Elafibranor in Adult Participants With Primary Sclerosing Cholangitis.
Elafibranor 80 mg, Elafibranor 120 mg, Placebo Matched to Elafibranor 80 mg - Primary Sclerosing Cholangitis
Phase 2Active not recruitingIpsen682022-12-292026-10-23
Evaluation of the Safety and Efficacy of HK-660S in Patients With Primary Sclerosing Cholangitis
HK-660S, Placebo - Primary Sclerosing Cholangitis
Phase 2CompletedCuromeBiosciences232021-10-282023-07-27
A Study of HTD1801 in Adolescents With Primary Sclerosing Cholangitis (PSC)
HTD1801, Ursodeoxycholic Acid - Primary Sclerosing Cholangitis, Cholangitis
Phase 2WithdrawnHighTide Therapeutics (Hong Kong) Limited2021-03-012026-08-12
A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Sclerosing Cholangitis (PSC)
Volixibat, Placebo - Primary Sclerosing Cholangitis
Phase 2Active not recruitingMirum Pharmaceuticals, Inc.1822020-12-182026-10-19
CM-101 in PSC Patients -The SPRING Study
Anti-human CCL24 monoclonal antibody (CM-101), Placebo - Primary Sclerosing Cholangitis
Phase 2CompletedChemomAb Ltd.772020-10-012026-07-02
Phase 2a Evaluation of Safety, Tolerability, and Pharmacokinetics of PLN-74809 in Patients With Primary Sclerosing Cholangitis (PSC)
PLN-74809, Placebo - Primary Sclerosing Cholangitis
Phase 2CompletedPliant Therapeutics, Inc.1212020-07-272026-01-23
Vancomycin for Primary Sclerosing Cholangitis
Vancomycin, Placebo - Primary Sclerosing Cholangitis
Phase 2 / Phase 3TerminatedElizabeth Carey1022020-01-232026-10-21
A Study to Evaluate the Safety, and Tolerability, and Efficacy of Seladelpar in Patients With PSC
Seladelpar, Placebo to match Seladelpar - Primary Sclerosing Cholangitis
Phase 2TerminatedGilead Sciences12019-11-122025-01-16
Vidofludimus Calcium for Primary Sclerosing Cholangitis
Vidofludimus calcium - Primary Sclerosing Cholangitis
Phase 2CompletedElizabeth Carey182019-06-172022-10-17

Showing 20 of 34. Sign in to see all of them.

Narrower conditions

Cholangitis, Sclerosing (34)  ·  Cholangitis (3)  ·  Digestive System Diseases (3)  ·  Bile Duct Diseases (2)  ·  Biliary Tract Diseases (2)  ·  Cholestasis (2)  ·  Inflammatory Bowel Diseases (2)  ·  Colitis, Ulcerative (1)  ·  Liver Cirrhosis, Biliary (1)  ·  Pruritus (1)

Broader conditions

Bile Duct Diseases (32)  ·  Biliary Tract Diseases (32)  ·  Cholangitis (31)  ·  Digestive System Diseases (31)  ·  Gastroenteritis (3)  ·  Gastrointestinal Diseases (3)  ·  Intestinal Diseases (3)  ·  Pathological Conditions, Signs and Symptoms (2)  ·  Cholestasis, Intrahepatic (1)  ·  Colitis (1)  ·  Colonic Diseases (1)  ·  Fibrosis (1)  ·  Inflammatory Bowel Diseases (1)  ·  Liver Cirrhosis (1)  ·  Liver Diseases (1)

Interventions

Fenofibrate (2)  ·  Ursodeoxycholic Acid (2)  ·  Vancomycin (2)  ·  aldafermin (2)  ·  (2-methyl-4-(5-methyl-2-(4-trifluoromethyl-phenyl)-2H-(1,2,3)triazol-4-ylmethylsulfanyl)phenoxy)acetic acid (1)  ·  2-(2,6-dimethyl-4-(3-(4-(methylthio)phenyl)-3-oxo-1-propenyl)phenoxyl)-2-methylpropanoic acid (1)  ·  Blood Specimen Collection (1)  ·  Curcumin (1)  ·  Hymecromone (1)  ·  Mitomycin (1)  ·  Pharmaceutical Preparations (1)  ·  Saline Solution (1)  ·  Sulfasalazine (1)  ·  Thalidomide (1)  ·  cenicriviroc (1)

Sponsors

Mayo Clinic (4)  ·  Brigham and Women's Hospital (2)  ·  Elizabeth Carey (2)  ·  Gilead Sciences (2)  ·  NGM Biopharmaceuticals, Inc (2)  ·  University of Birmingham (2)  ·  Albireo, an Ipsen Company (1)  ·  Aparna Goel (1)  ·  Cascade Pharmaceuticals, Inc (1)  ·  ChemomAb Ltd. (1)  ·  CuromeBiosciences (1)  ·  Dr. Falk Pharma GmbH (1)  ·  Durect (1)  ·  Fuzhou General Hospital (1)  ·  Galmed Pharmaceuticals Ltd (1)

Countries

United States (22)  ·  United Kingdom (8)  ·  Canada (6)  ·  Germany (5)  ·  France (4)  ·  Italy (4)  ·  Spain (4)  ·  Austria (3)  ·  Netherlands (3)  ·  Australia (2)  ·  Belgium (2)  ·  Israel (2)  ·  Poland (2)  ·  Argentina (1)  ·  Brazil (1)

Top investigators

Elizabeth Carey, MD (2)  ·  Alastair Smith, MD (1)  ·  Aparna Goel, MD (1)  ·  Arun Sanyal, MD (1)  ·  Azita Hekmatdoost, MD, PhD (1)  ·  Channa Jayasekera (1)  ·  Cynthia Levy, MD (1)  ·  Do-hyun Park (1)  ·  J.P. Nicandro (1)  ·  Jason Sluzevich, MD (1)  ·  Joshua A Korzenik, MD (1)  ·  Joshua R Korzenik, MD (1)

Results publications

PMID 19585548, PMID 28529147, PMID 28674140, PMID 30661255, PMID 33681680, PMID 33898959, PMID 37055910, PMID 39762111, PMID 40350321, PMID 41016442, PMID 41513411, PMID 42489629

NIH funding

2014 (1), 2015 (1), 2016 (1), 2019 (1), 2023 (1), R01DK056924 (1)